BrainAurora Adds Directors’ Responsibility Statement to Earlier Placing Announcement

An announcement from BrainAurora Medical Technology Limited ( (HK:6681) ) is now available.

BrainAurora Medical Technology Limited issued a clarification stating that its directors collectively accept full responsibility for the accuracy and completeness of information in a prior announcement dated 23 January 2026 concerning a placing and top-up subscription. The company emphasised that, aside from the omission and now inclusion of this formal responsibility statement, all other details in the earlier announcement remain unchanged, aiming to reinforce regulatory compliance and transparency for investors and other stakeholders.

The most recent analyst rating on (HK:6681) stock is a Sell with a HK$5.50 price target. To see the full list of analyst forecasts on BrainAurora Medical Technology Limited stock, see the HK:6681 Stock Forecast page.

More about BrainAurora Medical Technology Limited

BrainAurora Medical Technology Limited is a Hong Kong-listed medical technology company incorporated in the Cayman Islands, operating in the healthcare and medtech sector. The company is governed by a board comprising an executive director, several non-executive directors and independent non-executive directors, reflecting standard corporate governance structures for listed medical technology firms in the region.

Average Trading Volume: 18,735,240

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$6.94B

See more data about 6681 stock on TipRanks’ Stock Analysis page.